Options For Engineering Bone

Burgess, Elisa A.; Hollinger, Jeffrey O.

doi:10.1016/b978-008042689-1/50022-4

Cited by 6 publications

(3 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[19][20][21] Moreover, PL is a well-characterized homopolymer and offers the advantages of synthesis and postsynthesis reproducibility, paramount to clinical success in satisfying consistency of responses. 22,23 In addition, by adding type I collagen to the PL, we predicted enhancement of cell attachment and BMP distribution, 8,[24][25][26][27] thereby fortifying fundamental properties for a tissue-engineered bone biomimetic. Therefore, our hypotheses for this study were the biomimetic composite PL and type I collagen (PLC)/ OPCs/recombinant human BMP-2-(rhBMP-2) would promote more new bone formation in critical-sized defects (CSDs) than the other treatments and bone formation would be time dependent.…”

Section: Introductionmentioning

confidence: 99%

Tissue-engineered bone biomimetic to regenerate calvarial critical-sized defects in athymic rats

Winn

Schmitt

Buck

et al. 1999

J. Biomed. Mater. Res.

Self Cite

View full text Add to dashboard Cite

A tissue-engineered bone biomimetic device was developed to regenerate calvaria critical-sized defects (CSDs) in athymic rats. Well-documented evidence clearly confirms that left untreated, CSDs will not spontaneously regenerate bone. To accomplish regeneration, four candidate treatments were assessed: porous poly(D,L-lactide) and type I collagen (PLC), PLC and human osteoblast precursor cells (OPCs) at 2 x 10(5) (PLC/OPCs), PLC and 50 microg of recombinant human bone morphogenetic protein-2 (PLC/rhBMP-2), and PLC/OPCs/rhBMP-2 (the bone biomimetic device). The hypotheses for this study were PLC/OPCs/rhBMP-2 would promote more new bone formation in CSDs than the other treatments and the amount of bone formation would be time dependent. To test the hypotheses, outcomes from treatments were measured at 2 and 4 weeks postoperatively by radiomorphometry for percent radiopacity and by histomorphometry for square millimeters of new bone formation. Data were analyzed by analysis of variance and Fisher's protected least significant difference for multiple comparisons with p< or = 0.05. At 2 and 4 weeks, radiomorphometric data revealed PLC/rhBMP-2 and PLC/OPCs/rhBMP-2 promoted significantly more radiopacity than either PLC or PLC/OPCs. Histomorphometry data at 2 and 4 weeks indicated significantly more new bone formation for PLC/rhBMP-2, PLC/OPCs/rhBMP-2, and PLC/OPCs compared to PLC. By 4 weeks, PLC/OPCs/rhBMP-2 and PLC/rhBMP-2 had regenerated the CSDs with more new bone than the other treatments; the quantity of bone at 4 weeks for these treatments was greater than at 2 weeks.

show abstract

Section: Introductionmentioning

confidence: 99%

Tissue-engineered bone biomimetic to regenerate calvarial critical-sized defects in athymic rats

Winn

Schmitt

Buck

et al. 1999

J. Biomed. Mater. Res.

Self Cite

View full text Add to dashboard Cite

show abstract

“…In summary, data originating from these different experiences conducted both in vitro and in vivo demonstrate that tissue engineering of bone can become an alternative therapeutic tool in the hand of the physician for the treatment of bone loss (Burgess and Hollinger, 1998).…”

Section: Cellular Approaches For Tissue Engineering Of Bonementioning

confidence: 99%

Tissue Engineering

Abatangelo

Brun

Radice

et al. 2002

Integrated Biomaterials Science

View full text Add to dashboard Cite

“…So far, more than 15 BMPs have been identified, including cartilage-derived morphogenetic proteins (CDMPs) 1, 2 and 3, which are also referred to, respectively, as growth and differentiation factors (GDFs) 5, 6, and 7 (Chang et al, 1994;Ripamonti and Reddi, 1997;Reddi, 1998). The TGF-~ superfamily is composed of at least 25 members including BMPs (except for BMP-1), TGF-~1-5 and CDMPs (Burgess and Hollinger, 1998;Iqbal et al, 2000;O'Connor et al, 2000). Only TGF-~1-3 have been identified in mammals.…”

Section: Growth Factors Associated With Cartilage and Bone Tissuesmentioning

confidence: 99%

6.9 Tissue Engineering of Human Cartilage

Weerda¹

2007

Surgery of the Auricle: Tumors-Trauma-Defects-Abnormalities

View full text Add to dashboard Cite

2.4.4 Trypan blue for viability test 2.5 Polymer Scaffold iv 2.6 Seeding Equipment 2. 7 Bioreactor System 2.8 Isolation of Chondrocytes from Cartilage Tissue 2.9 Culture of Chondrocytes in T-Flasks 2.9.1 Primary chondrocyte cultures 2.9.2 Harvesting, freezing and passaging of chondrocytes 2.1 O Culture of Osteoblast-Like Cells in T-Flasks 2.10.1 Primary explant bone cultures 2.10.2 Harvesting, freezing and passaging of osteoblast-like cells 2.11 Seeding Chondrocytes onto the Polymer Scaffold 2.11.1 Seeding chondrocytes in side-arm flasks using syringe needles 2.11.2 Seeding chondrocytes in side-arm flasks using double flanges 2.11.3 Seeding chondrocytes in bioreactors using a test-tube shaker 2.12 Seeding Osteoblast-Like Cells onto the Polymer Scaffold 2.13 Cultivation of Tissue-Engineered Constructs in Bioreactors 2.13.1 Bioreactor operation 2.13.2 Preliminary experiments 2.13.3 Medium flow rate studies 2.13.4 Seeding system studies 2.13.5 Effect of initial seeding density 2.13.6 Effect of medium replacement regime 2.13. 7 Effect of polymer scaffold thickness 2.13.8 Direction of medium flow through the PGA discs 2.13.9 Effect of suturing two pieces of polymer scaffold together 2.13.10 Effect of periodically reversing the direction of medium flow 2.13.11 Co-cultivation of ex-vivo cartilage and ex-vivo bone tissues V vi with tissue-engineered cartilage 2.13.12 Co-cultivation of tissue-engineered cartilage with tissueengineered bone 2.13.13 Effect of diacerein 2.14 Analysis of Tissue-Engineered Constructs and Culture Medium 2.14.1 Tissue wet weight 2.14.2 Preparation of tissue-engineered constructs for analysis 2.14.3 Biochemical analyses 2.14.3.1 Digestion of cartilage tissues with papain 2.14.3.2 Digestion of cartilage tissues with proteinase K 2.14.3.3 Cell number 2.14.3.4 Glycosaminoglycans (GAG) 2.14.3.5 Total collagen 2.14.3.6 Collagen type II 2.14.4 Histology 2. 14. 4. 1 Staining of cell-seeded polymer pieces for cells 2.14.4.2 Staining of tissue-engineered constructs and native cartilage tissues for cells and extracellular matrix (ECM) 2.14.5 lmmunohistochemistry 2.14.6 Scanning electron microscopy (SEM) 2.14. 7 Transmission electron microscopy (TEM) 2.14.8 Glucose and lactate 2. 15 Statistical Analysis of Data 2.16 Hydrodynamic Conditions in the Seeding Flasks and Bioreactors 2.16.1 Seeding flasks 2.16.2 BioreactorsCHAPTER 3 -RESULTS 3.1 Culture of Chondrocytes in T-Flasks 3.2 Culture of Bone Cells in T-Flasks 3.3 Preliminary Experiments 3.4 Medium Flow Rate Studies 3.5 Seeding Systems 3.6 Effect of Initial Seeding Density 3. 7 Effect of Medium Replacement Regime 3.8 Effect of Polymer Scaffold Thickness and Initial Seeding Density 3.9 Properties of Freshly-Seeded PGA Scaffolds 3.9.1 PGA discs seeded with chondrocytes 3.9.2 PGA seeded with bone cells 3.10 Direction of Medium Flow through PGA Discs 3.11 Effect of Suturing Two Pieces of Polymer Scaffold Together 3.12 Effect of Periodically Reversing the Direction of Medium Flow 3.13 Co-Cultivation of Ex-Vivo Cartilage, Ex-Vivo Bone and Tissue-Engineered Bone ...

show abstract

Options For Engineering Bone

Cited by 6 publications

References 77 publications

Tissue-engineered bone biomimetic to regenerate calvarial critical-sized defects in athymic rats

Tissue-engineered bone biomimetic to regenerate calvarial critical-sized defects in athymic rats

Tissue Engineering

6.9 Tissue Engineering of Human Cartilage

Contact Info

Product

Resources

About